Literature DB >> 3674059

Treatment of idiopathic mixed cryoglobulinemia with alpha interferon.

L Bonomo1, M Casato, A Afeltra, D Caccavo.   

Abstract

Seven patients with type II idiopathic mixed cryoglobulinemia were treated with recombinant human leukocyte interferon (alpha interferon). In all of them, a conspicuous reduction of circulating cryoglobulins was noted, together with a definite, remarkable improvement of the clinical pattern. The immunologic parameters (natural killer cell activity and phagocytosis, among others) improved as well; side effects were usually mild and transient. Increases in the cryoglobulin level occurred in a few cases, but they were at least partly sensitive to readministration of alpha interferon treatment. The favorable results obtained in these cases of idiopathic cryoglobulinemia seem to be consistent and prolonged.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3674059     DOI: 10.1016/0002-9343(87)90904-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  22 in total

1.  A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group.

Authors:  X Mariette; C Chastang; P Clavelou; J P Louboutin; J M Leger; J C Brouet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  Hepatitis C: a possible etiology for cryoglobulinaemia type II.

Authors:  A Pechère-Bertschi; L Perrin; P de Saussure; J J Widmann; E Giostra; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

Review 3.  Mixed cryoglobulinemia as a model of systemic vasculitis.

Authors:  F Dammacco; D Sansonno
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 4.  [Hepatitis associated cryoglobulinemia].

Authors:  S Pischke; M Cornberg; M P Manns
Journal:  Internist (Berl)       Date:  2008-03       Impact factor: 0.743

Review 5.  Cryoglobulins and cryoglobulinemia. Diagnostic and therapeutic considerations.

Authors:  A Della Rossa; G Trevisani; S Bombardieri
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 6.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus.

Authors:  P Cresta; L Musset; P Cacoub; L Frangeul; D Vitour; T Poynard; P Opolon; D T Nguyen; F Golliot; J C Piette; J M Huraux; F Lunel
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

8.  Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.

Authors:  Joel S Emery; Magdalena Kuczynski; Danie La; Saeed Almarzooqi; Matthew Kowgier; Hemant Shah; David Wong; Harry L A Janssen; Jordan J Feld
Journal:  Am J Gastroenterol       Date:  2017-03-14       Impact factor: 10.864

9.  Long-term results regarding the use of recombinant interferon alpha-2b in the treatment of II type mixed essential cryoglobulinemia.

Authors:  V M Lauta; M A De Sangro
Journal:  Med Oncol       Date:  1995-12       Impact factor: 3.064

10.  Rituximab in cryoglobulinemic peripheral neuropathy.

Authors:  Roberto Cavallo; Dario Roccatello; Elisa Menegatti; Carla Naretto; Franca Napoli; Simone Baldovino
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.